AZ1366 - Moligand™ , Inhibitor of poly(ADP-ribose) polymerase 1;Inhibitor of poly(ADP-ribose) polymerase 2;Inhibitor of tankyrase;Inhibitor of tankyrase 2, CAS No.1645286-58-3, Inhibitor of poly(ADP-ribose) polymerase 1;Inhibitor of poly(ADP-ribose) polymerase 2;Inhibitor of tankyrase;Inhibitor of tankyrase 2
AZ1366 - Moligand™ , Inhibitor of poly(ADP-ribose) polymerase 1;Inhibitor of poly(ADP-ribose) polymerase 2;Inhibitor of tankyrase;Inhibitor of tankyrase 2, CAS No.1645286-58-3, Inhibitor of poly(ADP-ribose) polymerase 1;Inhibitor of poly(ADP-ribose) polymerase 2;Inhibitor of tankyrase;Inhibitor of tankyrase 2
GRADE & PURITYMoligand™?Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools.
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
Reconstitution Calculator
Revisões
Avaliações dos Clientes
Application Protocols
Validated, item-specific protocols are not provided for this product listing.
General guidance for small-molecule screening compounds
Stock solution: Prepare in DMSO (e.g., 10–50 mM). Store aliquots to minimize freeze–thaw and moisture exposure.
Dose–response setup: Perform serial dilutions (e.g., 10-point, 3-fold) to cover anticipated potency ranges. Include vehicle controls matching the highest DMSO percentage.
Assay compatibility: Verify the maximum tolerated DMSO level for your assay (common ranges 0.1–1% v/v). Inspect wells for precipitation; mix thoroughly.
Data quality: Include positive/negative controls and replicate wells; monitor Z′-factor for HTS robustness. Confirm hits with orthogonal/secondary assays.
For detailed, validated protocols tied to a specific biological target or assay platform, consult primary literature associated with AZ1366 (see PubChem CID 137213562) or your internal SOPs.
Biological Roles
Item-specific biological targets and mechanisms are not provided in the product data for AZ1366. As supplied, it is intended strictly for research use in discovery and screening contexts.
General considerations (literature context)
Small molecules in Moligand™ collections are commonly used as chemical probes or reference compounds to interrogate cellular pathways, enzyme activities, or protein–protein interactions in vitro. Any functional annotation for AZ1366 should be drawn from primary literature or trusted databases (e.g., PubChem CID 137213562) and validated experimentally in the user’s assay system.
Best practices
Verify reported activities with independent dose–response experiments, including appropriate positive/negative and vehicle controls.
Evaluate cytotoxicity and off-target effects at relevant concentrations using orthogonal assays.
Consider solubility, stability, and protein binding in the chosen media when interpreting potency and efficacy metrics.
Compliance note
No medical, diagnostic, or therapeutic applications are implied. This product is for laboratory research use only.
Buffer Applications
AZ1366 is a discrete small molecule and is not a buffering agent. Therefore, buffer formulation guidance (pKa-based recipes, pH ranges) is not typically applicable.
Practical assay considerations
When preparing working solutions, dilute DMSO stocks into the assay buffer of choice (e.g., PBS, HBSS, cell culture media) while maintaining solvent percentages compatible with the biological system.
To minimize compound precipitation upon dilution, add the DMSO stock slowly to vigorously mixed buffer/media, or pre-dilute stepwise.
For actual buffer system design, please refer to dedicated buffering agents (e.g., HEPES, Tris, phosphate) and consult their respective application notes.
Green Alternatives
Context: For screening compounds like AZ1366, the main environmental impact relates to solvent choice and solution preparation rather than the compound serving as a reagent.
Greener handling strategies
Prefer DMSO for stock solutions over halogenated or high-toxicity solvents. Maintain low working percentages (≤0.1–0.5% v/v) in aqueous assays to minimize solvent burden.
When volatile organic co-solvents are necessary, consider ethanol or isopropanol instead of DMF/NMP where solubility permits.
Implement microscale assay formats (384/1536-well) to reduce solvent usage and waste.
Use closed, low-dead-volume dispensing to limit evaporative losses and operator exposure.
Comparison of common stock solvents (general guidance)
DMSO: High solvency, good assay tolerance; low volatility; relatively favorable EHS profile compared to DMF/NMP.
Ethanol: Renewable feedstocks available; higher volatility; lower solvency for many drug-like molecules.
DMF/NMP: Strong solvency but higher EHS concerns; reserve for cases where necessary and ensure proper controls.
Note: No item-specific green alternative exists for the compound itself; optimization should focus on greener solvents, minimized scale, and efficient waste segregation per institutional green chemistry practices.
Pharmaceutical Uses
No pharmacopeial or excipient role is specified for AZ1366. This product is not intended for human or veterinary use and has no approved pharmaceutical application.
Research/formulation context (general)
In preclinical discovery, small molecules may be formulated into DMSO-based stocks for in vitro testing. For in vivo method development (if applicable under institutional approvals), co-solvent systems (e.g., PEG400/saline with low DMSO, or Captisol) are sometimes explored; however, no item-specific formulation recommendations are provided here.
Regulatory note
Not a drug substance or excipient. No USP/EP/JP monograph applicability. For any regulated use, separate sourcing and full CMC characterization would be required.
Item-specific status
Pharmaceutical/clinical uses: Not applicable.
Grade: Moligand™ (research screening grade only).
Physical Properties
Item-specific physicochemical constants have not been provided for this listing.
Appearance: Not specified for this item; refer to CoA/Spec Sheet.
Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
Melting point: Not specified for this item; refer to CoA/Spec Sheet.
Boiling point: Not applicable/reported for discrete drug-like solids; decomposition may occur before boiling (general note).
Density: Not specified for this item; refer to CoA/Spec Sheet.
LogP/logD, pKa, refractive index: Not specified for this item; refer to CoA/Spec Sheet.
Solubility (practical guidance): For small-molecule screening compounds, initial stock solutions are commonly prepared in anhydrous DMSO (e.g., 10–50 mM). Solubility in aqueous buffers generally requires co-solvent (DMSO) or cosolubilization with a small percentage of ethanol/DMF. Actual solubility limits are compound-dependent and should be verified experimentally.
Notes on literature/computed values
Public databases (e.g., PubChem CID 137213562) may list calculated properties (cLogP, HBD/HBA counts, TPSA). Those values, when consulted, should be treated as literature/computational estimates, not specifications for this supplied lot.
Quality and Grades
Grade: Moligand™ (product data)
What Moligand™ signifies
Intended use: Discovery/screening-grade small molecule suitable for assay development, SAR exploration, and reference control experiments in medicinal chemistry and chemical biology.
Typical QC elements for Moligand™ offerings (general description):
Identity confirmation by LC–MS and/or NMR.
Analytical purity assessment by HPLC/UPLC with UV (and, where applicable, MS) detection.
Batch-specific data are reported on the Certificate of Analysis.
What is NOT specified for this item
Exact purity percentage, residual solvent content, water content, metal limits, and absorbance/UV cutoffs: Not specified for this item; refer to CoA/Spec Sheet.
Stabilizers or counter-ions (if any): Not specified for this item; refer to CoA/Spec Sheet.
Implications for use
Moligand™ grade compounds are appropriate for in vitro biochemical and cell-based screening. For applications requiring ultra-high purity, formal pharmacopeial compliance, or trace-impurity certification, contact us for available higher-grade options or request expanded QC documentation for this lot.
Reaction and Applications
Primary use case: AZ1366 is supplied as a ready-to-use screening/reference compound rather than a synthetic reagent.
Research applications (general, non-clinical)
Chemical biology and target validation studies as a small-molecule probe in discovery workflows.
Positive/negative control in biochemical or cell-based assays, dose–response characterization, and mechanism-of-action hypothesis testing (where appropriate; consult literature and CoA).
Analytical reference standard for LC–MS method development and stability-indicating assays in support of screening campaigns.
Practical guidance for assay preparation
Prepare concentrated DMSO stocks (e.g., 10–50 mM) and dilute into assay media to final solvent levels compatible with the system (commonly ≤0.1–0.5% v/v DMSO).
Employ serial dilutions (e.g., 3-fold or 10-fold) to build potency curves; include vehicle controls.
Confirm solubility and absence of precipitation by visual inspection and, if necessary, nephelometry or UV/vis scan.
Not a general-purpose reagent
AZ1366 is not typically used as a coupling partner, catalyst, or auxiliary in synthetic chemistry. For synthetic transformations, refer to the Synthetic Utility and Reaction Conditions sections for general considerations; however, reagent-like applications are limited for this item.
Reaction Conditions
Classical synthetic reaction conditions are not typically applicable to AZ1366 in its role as a finished screening compound. However, the following practical conditions relate to solution handling and assay preparation:
Stock preparation: Dissolve in anhydrous DMSO to prepare concentrated stocks (e.g., 10–50 mM). Vortex and, if needed, sonicate briefly to aid dissolution. Record exact concentration by weight-in/volume or by quantitative NMR where precision is required.
Working solutions: Dilute stocks into assay buffers/media while maintaining acceptable final DMSO (commonly ≤0.1–0.5% v/v for many cell-based assays; verify tolerance in your system).
Filtration: For sterile applications, pass working solutions through 0.22 µm filters (PTFE/PES/RC as compatible with solvent composition).
Stability checks: Monitor for precipitation or discoloration. Where feasible, confirm concentration by UV–vis or LC–MS at time-zero and after incubation to assess stability under assay conditions.
Note: If you intend to perform chemical transformations on AZ1366 (e.g., prodrug formation, linker installation), consult the public structure and relevant literature for reaction-specific conditions. No item-specific synthetic conditions are provided here.
Safety and Handling
Safety data for this specific item have not been fully specified in the product data.
GHS classification: Not specified for this item; refer to SDS.
Signal word / H-statements / pictograms: Not specified for this item; refer to SDS.
General laboratory precautions (best practice):
Handle in a fume hood to avoid inhalation of dust/aerosols.
Wear appropriate PPE: lab coat, safety glasses, and suitable chemically resistant gloves (e.g., nitrile). Avoid skin and eye contact.
Prevent ingestion and inhalation; avoid creating dust.
Storage incompatibilities (general): Keep away from strong oxidizers and strong acids/bases unless stability is verified. Avoid prolonged exposure to light and moisture until stability is confirmed from the CoA/SDS.
First-aid overview (general):
Skin/eye contact: Rinse with water for several minutes; remove contaminated clothing; seek medical attention if irritation persists.
Inhalation: Move to fresh air; seek medical attention if symptoms occur.
Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
Fire-fighting measures (general): Use CO2, dry chemical, or foam. Combustion may produce COx/NOx depending on composition.
Always consult the Safety Data Sheet (SDS) for authoritative, product-specific guidance.
Solvent Selection
As a discovery small molecule, AZ1366 is commonly handled as concentrated DMSO stock solutions for screening.
Primary solvent for stocks (general best practice): Anhydrous DMSO due to broad solvency for drug-like compounds and assay compatibility at ≤0.1–1% v/v in many biological assays.
Alternative solvents (depending on structure/assay tolerance):
DMF or NMP for challenging solubility (ensure compatibility with assay systems).
Ethanol or isopropanol for some biochemical assays; often co-dosed at low percentages.
Aqueous buffers typically require DMSO cosolvent; direct dissolution in water is often limited for hydrophobic scaffolds.
Degassing/filtration: Sterile filtration (0.22 µm PTFE/PES) of working solutions may be used for cell-based assays to ensure clarity and sterility.
Comparison (general)
DMSO vs DMF: DMSO offers better biocompatibility and is preferred for most screening. DMF can improve solubility but may be cytotoxic at lower percentages.
DMSO vs ethanol: Ethanol is volatile and less polar; can be preferable where lower DMSO tolerance exists, but solubility is typically lower for polar heteroaromatics.
Note: Actual solubility limits for AZ1366 are not specified for this item; determine empirically or consult literature databases (PubChem CID 137213562).
Storage and Reconstitution
Storage conditions: Room temperature (product data). Protect from excessive heat, light, and moisture as a general precaution for small molecules. Keep container tightly closed.
Shipped in: Not specified for this item; refer to CoA/Spec Sheet.
Appearance: Not specified for this item; refer to CoA/Spec Sheet.
Reconstitution and handling (general guidance)
Solvent: Use anhydrous DMSO to prepare concentrated stock solutions (e.g., 10–50 mM). If alternative solvents are needed (DMF, ethanol), verify solubility and assay compatibility.
Aliquoting: Prepare single-use aliquots to minimize repeated freeze–thaw and moisture ingress. Clearly label concentration and date.
Short-term storage of solutions: DMSO stocks are commonly stored at 2–8°C or −20°C, protected from light. Actual stability is compound-dependent; assess by LC–MS or HPLC where critical. For this item, no solution stability is specified—verify empirically.
Freeze–thaw: Minimize cycles; thaw at ambient temperature and mix gently before use.
Specifications not provided for this item
Water content, residual solvents, stabilizers, and shelf life: Not specified for this item; refer to CoA/Spec Sheet.
Research Use Only: Not for human or veterinary use.
Structure and Identity
Brief overview: AZ1366 is offered as a research-only small molecule in our Moligand™ collection, suitable for screening and reference use in discovery workflows.
SKU: A607835
Product name: AZ1366
CAS: 1645286-58-3 (product data)
PubChem CID: 137213562 (product data)
InChIKey: 280406 (product data; provided as-is)
SMILES: Not specified for this item; refer to CoA/Spec Sheet.
Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
Structural notes
Item-specific structural features (functional groups, ring systems, stereochemistry): Not specified for this item; consult the structure depiction in public databases (e.g., PubChem CID 137213562) or the product CoA.
2D description (general): AZ1366 is a discrete, single-component organic small molecule intended for biochemical/biological screening. Without an item-specific structural disclosure (SMILES/InChI), detailed functional group annotation is not provided here.
Identity confirmation guidance (general)
Typical orthogonal IDs used for Moligand™ compounds include LC–MS (observed m/z vs. calc.), 1H NMR, and analytical HPLC purity. For definitive identifiers and batch-specific data, see the accompanying Certificate of Analysis (CoA).
Synthetic Utility
AZ1366 is supplied as a final small molecule for screening and is not generally employed as a synthetic reagent, catalyst, or building block.
Potential laboratory roles (general)
Analytical reference standard for method development (e.g., LC–MS retention time marking, stability-indicating methods) in support of discovery workflows.
Positive control material in chemical biology assays.
Limitations
Lacking a disclosed SMILES/structure in the product data, no specific functional group reactivity or derivatization routes can be recommended for this item.
If derivatization or tagging is desired (e.g., biotinylation/fluorophore conjugation for pull-downs or imaging), consult the publicly available structure (PubChem CID 137213562) to assess feasible vectors and maintain core integrity; perform new characterization after modification.
Bottom line
Treat AZ1366 as a probe/reference compound rather than as a general-purpose reagent. For synthetic transformations or scaffold modifications, rely on primary literature associated with the compound’s structure and validate any new derivatives with full analytical characterization.
Target Specificity
Item-specific biological target, selectivity profile, and binding constants are not provided in the product data for AZ1366.
Target(s): Not specified for this item; refer to CoA/Spec Sheet and primary literature.
Species reactivity, assay class, or pathway mapping: Not specified for this item; refer to CoA/Spec Sheet and primary literature.
Users should consult peer-reviewed sources and verify target engagement using orthogonal assays in their specific experimental context.
Need help choosing the grade?
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
